Correction: Purification and characterization of an antimicrobial compound against drug-resistant MRSA and VRE produced by Streptomyces levis strain HFM-2

Correction to: Scientific Reports 10.1038/s41598-025-10572-3, published online 18 July 2025

The original version of this Article contained an error in the order of the Figures. Figure 2 was published as figure 3, figure 3 was published as figure 4, figure 4 was published as figure 5, figure 5 was published as figure 6, figure 6 was published as figure 7 and figure 7 was published as figure 2.

Fig. 2.

Antibacterial activity of EtOAc extract and HFM-2P compound against (a) MRSA, (b) VRE, (c) E. coli, (d) S. aureus, (e) S. epidermidis, (f) K. pneumoniae sub sp. pneumoniae; (g) E. aerogenes, (h) B. subtilis, (i) C. herbarum, (j) F. oxysporum, (k) A. brassicicola, (l) C. gleosporoides E: EtOAc extract, P: Purified compound, T: Teicoplanin (30 µg/disc), M: Methicillin (10 µg/disc), V: Vancomycin (30 µg/disc).

Fig. 3.

Thin layer chromatography of HFM-2P compound from S. levis strain HFM-2 (a), Bioautography of HFM-2P compound against VRE (b), MRSA (c), and F. oxysporum (d) with Rf values of 0.65.

Fig. 4.

FT-IR spectrum of the purified HFM-2P compound.

Fig. 5.

¹HNMR of purified HFM-2P compound.

Fig. 6.

Structure of the purified compound HFM-2P as a 2,6-disubstituted chromone derivative.

Fig. 7.

The SEM (scanning electron micrographs) display the effect of HFM-2P compound on MRSA, VRE, E. coli, and B. subtilis; Control (untreated cells): (a) MRSA, (d) VRE, (g) E. coli; j) B. subtilis. Cells treated with HFM-2P compound: (b) MRSA, (e) VRE, (h) E. coli, and (k) B. subtilis. Positive control: (c) MRSA treated with vancomycin, (f) VRE treated with teicoplanin, i and l) E. coli and B. subtilis treated with gentamicin.

The original Figures are given below.

The original Article has been corrected.